Evidence map›Paper›PMID 37932011›Full record

ArticleGenes & development2023

Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR.

Dali Zong, Natasha C Koussa, James A Cornwell, Ajith V Pankajam, Michael J Kruhlak, Nancy Wong, Raj Chari, Steven D Cappell, André Nussenzweig

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dali ZongLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA; andre_nussenzweig@nih.gov dali_zong@nih.gov.ORCID 0000-0001-6019-2970
Natasha C KoussaLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
James A CornwellLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Ajith V PankajamLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Michael J KruhlakLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Nancy WongLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Raj ChariGenome Modification Core, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, USA.
Steven D CappellLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
André NussenzweigLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA; andre_nussenzweig@nih.gov dali_zong@nih.gov.
National Institutes of Health · USFrederick National Laboratory for Cancer Research · US

Funding

Control of cell cycle commitment by APCC-Cdh1ZIABC011830 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAPPELL, STEVEN · 2018 to 2025
$4.7M
Intramural NIH HHS ZIA BC011830NCI NIH HHS HHSN261201000031CNCI NIH HHS HHSN261201500001CNCI NIH HHS HHSN261201500001GNCI NIH HHS HHSN261201500001WNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003I
6 · The paper itself

Abstract

Addiction to the WRN helicase is a unique vulnerability of human cancers with high levels of microsatellite instability (MSI-H). However, while prolonged loss of WRN ultimately leads to cell death, little is known about how MSI-H cancers initially respond to acute loss of WRN-knowledge that would be helpful for informing clinical development of WRN targeting therapy, predicting possible resistance mechanisms, and identifying useful biomarkers of successful WRN inhibition. Here, we report the construction of an inducible ligand-mediated degradation system in which the stability of endogenous WRN protein can be rapidly and specifically tuned, enabling us to track the complete sequence of cellular events elicited by acute loss of WRN function. We found that WRN degradation leads to immediate accrual of DNA damage in a replication-dependent manner that curiously did not robustly engage checkpoint mechanisms to halt DNA synthesis. As a result, WRN-degraded MSI-H cancer cells accumulate DNA damage across multiple replicative cycles and undergo successive rounds of increasingly aberrant mitoses, ultimately triggering cell death. Of potential therapeutic importance, we found no evidence of any generalized mechanism by which MSI-H cancers could adapt to near-complete loss of WRN. However, under conditions of partial WRN degradation, addition of low-dose ATR inhibitor significantly increased their combined efficacy to levels approaching full inactivation of WRN. Overall, our results provide the first comprehensive view of molecular events linking upstream inhibition of WRN to subsequent cell death and suggest that dual targeting of WRN and ATR might be a useful strategy for treating MSI-H cancers.

Indexed as

DNA ReplicationNeoplasmsAtaxia Telangiectasia Mutated ProteinsDNA DamageDNA HelicasesExodeoxyribonucleasesHumansMicrosatellite RepeatsRecQ HelicasesWerner Syndrome HelicaseAtaxia Telangiectasia Mutated ProteinsATR protein, humanDNA HelicasesExodeoxyribonucleasesRecQ HelicasesWerner Syndrome HelicaseWRN protein, humanATRmicrosatellite instabilitysynthetic lethalityWRN

Identifiers

PMID37932011
PMCPMC10691471
OpenAlexW4388410087

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.